A biotech borne out of a JV between Bayer’s new research deals arm and CRISPR Therapeutics will start operations at life sciences hub Kendall Square in…

Johnson & Johnson ($JNJ) has partnered with a microbiome startup in its JLABS San Diego incubator to develop treatments for inflammatory skin diseases.

A snapshot survey of biotech chiefs during the second quarter has shown that their confidence to be able to raise funds has doubled since Q1, but they are a…

Bristol-Myers Squibb is adding to an existing partnership with Bavarian Nordic to start a Phase II combo trial of Opdivo with Bavarian’s cancer vaccine CV301…

Vedanta Biosciences has partnered with the NYU Langone Medical Center to develop microbiome-derived immunotherapies specifically for use paired with checkpoint…

Bristol-Myers Squibb is buying back Asia rights that it outlicensed to Aslan Pharmaceutical after almost 5 years--and some Phase I data.

Eli Lilly will continue its late-stage breast cancer cocktail trial after its CDK4/CDK6 candidate, when used alongside AstraZeneca’s marketed Faslodex (…

Partners Eisai and Biogen are moving their oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III. There they join other major biopharmas…

Editas Medicine has done a deal with gene therapy small cap Adverum to introduce genome editing into diseased retina via gene therapy vectors.